

## DAFTAR PUSTAKA

1. Cade JF. High risk of the critically ill for venous thromboembolism. *Crit Care Med* 1982;10:448-450.
2. Belch J J, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. *Scott Med J* 1981;26:115-117.
3. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. *JAMA* 1995;274:335-337.
4. Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. *Semin Thromb Hemost* 2002, 28(Suppl 2):3-13.
5. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: the eight American college of chest physicians evidence-based clinical practice guidelines. *Chest* 2008;133:381S-453S.
6. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease\* : American college of chest physicians evidence-based clinical practice guidelines (8th edition). *Chest* 2008;133; 454S-545S
7. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants\* : American college of chest physicians evidence-based clinical practice guidelines (8th edition). *Chest* 2008;133;141S-159S
8. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. *Ann Pharmacother* 2009;43:1064-83.
9. Levey SA, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med* 2003;139:137-47.

10. Metzger NL, Chesson MM. Subcutaneous Unfractionated Heparin for Treatment of Venous Thromboembolism in End-Stage Renal Disease. *Ann Pharmacother* 2010;44:2023-7.
11. Bentley PG, Kakkar VV, Scully MF, MacGregor IR, Webb P, Chan P, Jones N. An objective study of alternative methods of heparin administration. *Thrombosis Research* 1980;18:177-187.
12. Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Nilsson E, Wilhelmsson S, Zetterquist S. Subcutaneous Administration of heparin: a randomized comparison with intravenous administration of heparin to patients with deep-vein thrombosis. *Thrombosis Research* 1982;27:631-639.
13. Robinson AM, McLean KA, Greaves M, Channer KS. Subcutaneous versus intravenous administration of heparin in the treatment of deep vein thrombosis; which do patients prefer? a randomized cross-over study. *Postgrad Med J* 1993;69:115 – 116.
14. Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. *Ann Intern Med* 1992;116:279-84.
15. Sukrisman, Lugyanti. Trombosis Vena Dalam dan Emboli Paru. In: Sudoyo Aru W, et. al (eds.) Buku Ajar Ilmu Penyakit Dalam. 2nd ed. Jakarta Pusat: Fakultas Kedokteran Universitas Indonesia; 2007. p792
16. Venous Thrombosis: The Role of Genes, Environment, dan Behavior, ASH Education Book January 1, 2005 vol. 2005 no 11-12.
17. Andrews KL, Gamble GL, et al. Vascular Diseases. In: Delisa JA, editor. *Physical Medicine & Rehabilitation Principles and Practice*, 4th Edition. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 787-806.
18. Heit JA, Silverstein MD. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med*. 2000 (Mar 27); 160(6):809-15.
19. Deep vein thrombosis. National Heart, Lung, and Blood Institute. [http://www.nhlbi.nih.gov/health/dci/Diseases/Dvt/DVT\\_All.html](http://www.nhlbi.nih.gov/health/dci/Diseases/Dvt/DVT_All.html). Accessed May 29, 2011.

20. Fauci et al., editor. Venous Thrombosis. In: Harrison Principles of Internal Medicine. 17<sup>th</sup> ed. USA: The McGraw-Hill Companies; 2008.
21. Kessler C.M. The link between cancer and venous Thromboembolism: A review. *Am J Clin Oncol.* 2009;32: S3-S7.
22. Bombeli T, Spahn D.R. Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage. *Br J Anaesthesia*, 2004; 93: 275-87.
23. M, Nelson, D. Lehninger, Principles of Biochemistry. Freeman; 2004. p. 1100.
24. Katzung, Bertram G. 1994. Farmakologi Dasar dan Klinik. Jakarta: EGC. 33: 530-531.
25. Nader, HB et al. Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates. *Brazilian Journal Medical iology Research.* 1999; 32 (5): 529-538.
26. Mary J. Mycek et al. Farmakologi Ulasan Bergambar. Edisi2. Jakarta: Widya Medika. 2001; 20: 200-201.
27. Dewoto, R. Hedi. 2009. Antikoagulan, Antitrombotik, Trombolitik, dan Hemostatik. Jakarta: Fakultas Kedokteran UI; 51: 808-810.
28. Gupta S, Bhagotra A, Gulati S, Sharma J. Guidelines for the transport of critically ill patients: clinical guide. *JK Science* 2004; Vol. 6 No. 2: 109-112.
29. Hall, Guyton. 1997. Buku Ajar Fisiologi Kedokteran. Jakarta: ECG; 36: 580-581.
30. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? *Blood* 2009; 114: 759

## LAMPIRAN

### Lampiran 1. Hasil Output SPSS

#### a) Uji Normalitas


Tests of Normality

	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Trombosit 1	.112	15	.200*	.965	15	.778
Trombosit 2	.111	15	.200*	.977	15	.941
Trombosit 3	.157	15	.200*	.930	15	.275

\*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

#### b) Deskriptif Trombosit 1, 2, 3



### Descriptives

			Statistic	Std. Error
Trombosit 1	Mean		155353.33	20664.487
	95% Confidence Interval for Mean	Lower Bound	111032.42	
		Upper Bound	199674.25	
	5% Trimmed Mean		152781.48	
	Median		157000.00	
	Variance		6E+009	
	Std. Deviation		80033.215	
	Minimum		39000	
	Maximum		318000	
	Range		279000	
	Interquartile Range		105000	
	Skewness		.550	.580
	Kurtosis		-.138	1.121
	Trombosit 2	Mean		153306.67
95% Confidence Interval for Mean		Lower Bound	117049.19	
		Upper Bound	189564.14	
5% Trimmed Mean			151585.19	
Median			150000.00	
Variance			4E+009	
Std. Deviation			65472.529	
Minimum			49600	
Maximum			288000	
Range			238400	
Interquartile Range			82000	
Skewness			.351	.580
Kurtosis			-.080	1.121
Trombosit 3		Mean		154940.00
	95% Confidence Interval for Mean	Lower Bound	125244.21	
		Upper Bound	184635.79	
	5% Trimmed Mean		151544.44	
	Median		138000.00	
	Variance		3E+009	
	Std. Deviation		53623.659	
	Minimum		80000	
	Maximum		291000	
	Range		211000	
	Interquartile Range		56000	
	Skewness		.988	.580
	Kurtosis		1.824	1.121

c). T-Test

**Paired Samples Statistics**

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Trombosit 1	155353.33	15	80033.215	20664.487
	Trombosit 2	153306.67	15	65472.529	16904.934
Pair 2	Trombosit 1	155353.33	15	80033.215	20664.487
	Trombosit 3	154940.00	15	53623.659	13845.569
Pair 3	Trombosit 2	153306.67	15	65472.529	16904.934
	Trombosit 3	154940.00	15	53623.659	13845.569

**Paired Samples Correlations**

		N	Correlation	Sig.
Pair 1	Trombosit 1 & Trombosit 2	15	.972	.000
Pair 2	Trombosit 1 & Trombosit 3	15	.772	.001
Pair 3	Trombosit 2 & Trombosit 3	15	.855	.000

**Paired Samples Test**

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Trombosit 1 - Trombosit 2	2046.667	22532.39	5817.837	-10431.4	14524.7	.352	14	.730
Pair 2	Trombosit 1 - Trombosit 3	413.333	51489.76	13294.599	-28100.7	28927.4	.031	14	.976
Pair 3	Trombosit 2 - Trombosit 3	-1633.333	34047.46	8791.016	-20488.2	17221.5	-.186	14	.855

d) Deskripsi selisih jumlah trombosit

**Descriptive Statistics**

	N	Minimum	Maximum	Mean	Std. Deviation
Selisih Trombosit 1 - 2	15	-40000	27000	-2046.67	22532.385
Selisih Trombosit 1 - 3	15	-143000	46000	-413.33	51489.761
Selisih Trombosit 2 - 3	15	-103000	35500	1633.33	34047.460
Valid N (listwise)	15				

## **Lampiran 4. Biodata mahasiswa**

### **Identitas**

Nama : Wimardy Leonard Wijaya  
NIM : G2A009144  
Tempat/tanggal lahir : Bengkulu, 18 Agustus 1991  
Jenis kelamin : Laki-laki  
Alamat : Jalan Asem 1 79A Duri Kepa Jakarta Barat  
Nomor Telepon : 08170017655  
Email : [wimardy.leonard@gmail.com](mailto:wimardy.leonard@gmail.com)

### **Riwayat Pendidikan Formal**

1. SD St. Carolus Bengkulu (1997-2003)
2. SMP St Carolus Bengkulu (2003-2006)
3. SMA Kolese Kanisius Jakarta (2006-2009)
4. Fakultas Kedokteran Universitas Diponegoro (2009 - sekarang)

### **Keanggotaan Organisasi**

1. Wakil ketua PRMK FK UNDIP (2011-2012)